
Press Release|Articles|October 30, 2025
Camber Launches Abacavir and Lamivudine Tablets, USP
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Abacavir and Lamivudine Tablets, USP, for treating HIV-1 infection, enhancing access to essential treatments.
- The tablets contain 600 mg Abacavir and 300 mg Lamivudine, supplied in bottles of 30 tablets.
Advertisement
Continuing its mission to expand access to essential treatments, Camber Pharmaceuticals introduces Abacavir and Lamivudine Tablets, USP [a-BAK-a-veer-and-la-MIV-yoo-deen] to its portfolio.
Abacavir/Lamivudine Tablets, USP are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Camber's Abacavir and Lamivudine Tablets, USP (600 mg/300 mg) are supplied in bottles of 30 tablets.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 Boosters May Offer Head Start Against Future Animal Coronaviruses, But Immune "Imprinting" Complicates the Picture
2
Heal or Harm: Body Protective Compound-157 in the Gray Zone
3
Cardiovascular Inflammation Persists in Some Patients With CVD Despite Standard Treatment
4
FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis in Children as Young as 2
5











































































































